The Wilms' tumor 1 (WT1) gene on chromosome 11p13 encodes a Krupple-like zinc finger transcription factor that may act as a tumor suppressor or oncogene in leukemogenesis. 1 Mutations in WT1 were initially identified in 10-15% of acute myeloid leukemia (AML) and 20% of biphenotypic leukemia. 2 Recently, the frequency of 10-15% WT1 mutations in adult AML with normal karyotypes was confirmed using relatively large cohorts of AML patients. [3] [4] [5] [6] In some studies WT1 mutations were implicated as an independent adverse prognostic marker for patients with normal karyotype AML (o60 years); [2] [3] [4] [5] however, in other WT1 mutations did not have impact on outcome. 6 Mutations in WT1 in AML often result in frame shifts introducing premature termination codons (PTC), [2] [3] [4] [5] but it is not known whether WT1 mutant transcripts are degraded by the nonsense-mediated RNA decay (NMD) surveillance system. 7 Here, we analyzed a cohort of 218 AML cases for WT1 mutations by RT-PCR for mutations in exons 6 to 9 (WT1-FOR3 5 0 -GAGAGCGATAACCACACAAC-3 0 (exon6) and WT1-REV4 5 0 -CTGTATGAGTCCTGGTGTGGG-3 0 (exon9) (bp1214-1619 (NM_024426)) followed by denaturing high performance liquid chromatography (dHPLC, sensitivity 10-20% (mutation dosage)) and sequencing. In six AML cases missense and in-frame insertion mutations were detectable in WT1 (no. 1-6, Table 1 ). These WT1 missense and in-frame mutants are expressed, because these transcripts were readily detectable by RT-PCR. Analyses of a diagnostic and relapse sample of AML case no. 2270 (no. 7, Table 1 ), carrying a double mutation, showed that the out-of-frame WT1 mutations were not present on a single allele and both present at relapse. Thus, the insertions of 11 bp and 1 bp do not result in the expression of a WT1 protein with an internal frame-shift, but encode truncated WT1 proteins from two alleles.
Following this RT-PCR strategy; we detected relatively small numbers of WT1 mutations (2.7%). [2] [3] [4] [5] In contrast, out of a diverse AML cohort of 351 AML samples, we were able to reliably detect 21 insertion/deletion mutations in exon 7 or 9 of WT1 (no. 8-26, Table 1 ) using genomic DNA PCR 3,5 followed by dHPLC (sensitivity 10-20% (mutation dosage)) and sequencing. The overall frequency of WT1 mutations in AML patients with a normal karyotype was 6.3 and 7.7% in AML patients with normal karyotypes younger than 60 years. WT1 mutations were present in patients carrying a favorable karyotype, that is, t(8;21) (n ¼ 1), inv(16) (n ¼ 2) and t(15;17) (n ¼ 2) ( Table 1 ). This may suggest that mutations in WT1 cooperate with the fusion proteins AML1/ETO, CBFB/MYH11 and PML/RAR, respectively. WT1 mutations were more often present in AML with an FLT3 internal tandem duplication or NPM1 mutation (data not shown); however, none of these were statistically significant (Fisher's exact test). No association was found between WT1 mutations and other known acquired mutations in AML, that is, N-RAS-, K-RAS-or CEBPA mutations. By subcloning the WT1 PCR fragments of the five additional AML double mutants (Table 1) , we have shown that these were monoallelic. The overall WT1 mutation dosage was below 55%, thus, there is no direct indication that acquired uniparental disomy is involved in any of the AML cases. It is interesting to note that WT1 (1) WT1 mutations have recently been implicated as a poor prognostic factor in AML. [3] [4] [5] We investigated whether WT mutations carry prognostic value in our patient cohort. Univariate survival analyses of AML patients younger than 60 years by the method of Kaplan and Meier did not reveal any significant difference in overall (OS) and event-free survival (EFS) between patients with or without WT1 mutations (data not shown). These survival analyses were performed on all AML patients, except those with favorable cytogenetics (n ¼ 233) (OS P ¼ 0.09 and EFS P ¼ 0.08) or AML patients with normal karyotypes (n ¼ 134) (OS P ¼ 0.35 and EFS P ¼ 0.25).
All AML cases with genomic WT1 mutations were examined using RT-PCR. In 17 out of 21 cases WT1 mutations were detectable by PCR/dHPLC but undetectable by RT-PCR/dHPLC (no. 8-24, Table 1 ). The majority of these out-of-frame mutations were present in exon 7 of WT1. Thus, most AML cases do not express PTC-containing WT1 transcripts or at very low levels. To show the involvement of NMD, we selected three primary AML cases (no. 2275, no. 2305 and no. 3314 (no. 20-22, Table 1 )), which carried a WT1 insertion mutation as was shown by PCR on genomic DNA (WT1 mutation dosage 50% in all three AML cases based on PCR analysis), but not cDNA (Table 1) . We cultured these AMLs in the presence and absence of emetine (6 hours, 100 mg/ml). Emetine is known to block translation-mediated NMD. 7 The WT1 mutant mRNA transcripts are not detectable or present at low levels in AML cells cultured in the absence of emetine (Figure 1a) . Interestingly, however, the translation inhibitor prominently stabilized the WT1 mutant mRNA transcripts. After treatment with emetine the mutant WT1 transcripts are present at similar levels or even higher as the wild-type WT1 mRNA transcripts (Figure 1a) . By RQ-PCR with WT1 wild-type-and mutantspecific primers we showed a fourfold increase of mutant WT1 transcripts after emetine treatment relative to wild-type in case no. 2305. In fact, in case no. 3314 WT1 mutant transcripts were extremely low to undetectable before emetine treatment and highly abundant (4100000-fold increase) after treatment. The specificity of the mutant-specific primers was confirmed using AML cases without WT1 mutations. These results strongly indicate that WT1 transcripts with PTCs are sensitive to translation-mediated NMD. Importantly, in a diagnostic setting WT1 mutations may therefore be missed when mutation detection is based on RT-PCR.
PTCs are introduced as a result of insertion/deletion mutations in 77% of the AML cases. The three PTCs that are introduced in the majority of mutant WT1 transcripts (nt 1318PTC, nt 1345PTC and nt 1539PTC) are located over 55 bp upstream of the next intron boundary and are therefore prone to NMD. 7 However, PTC1621 that is present in AML patient no. 5365 should in theory not be affected by NMD because this PTC is located only 5 bp from the next intron boundary. In fact, this mutant transcript was indeed detectable by RT-PCR dHPLC. This case is in line with the involvement of NMD in the majority of WT1 mutant AML patients. In contrast, however, WT1 mRNA transcripts in AML cases no. 2270 and no. 5284, which contain nt 1394/1539 PTCs and nt 1539 PTC, respectively, were expressed. In these cases NMD may reduce the levels of PTC-containing mRNA suboptimal and truncated WT1 proteins may be expressed. In fact, it has been shown that PTC-containing mRNA is reduced by NMD to 5-25% levels. 7 At levels of 410% WT1 mutants will be detectable using the RT-PCR/dHPLC strategy.
To investigate the levels of WT1 protein in WT1 mutant cases, we selected three AML cases with WT1 insertion/deletion mutations (no. 2275, no. 2186, no. 1551 (no. 22-24, Table 1) ) and control wild-type WT1 AML samples and performed immunoprecipitations with an antibody specific for the N terminus of human WT1, which recognizes residues 1-180 (Figure 1b) . The predicted truncated WT1 proteins were not detectable in the selected WT1 mutant cases (no. 2275:42 kDa, no. 2186:42 kDa; no. 1551:41 kDa) and CTS cell line (49 kDa). 5 It is interesting to note that mutant WT1 mRNA is expressed in CTS (data not shown), which would suggest that the truncated WT1 protein is instable in this cell line. In contrast, wild-type WT1 (56 kDa) is expressed in all AML cases irrespective of the presence of WT1 mutations.
In conclusion, we identified in 218 AML patients a relatively low number of WT1 mutations by RT-PCR (2.7%), whereas by PCR on 351 AML cases additional WT1 mutations (6.0%) were detectable. WT1 mutations were present not only in normal karyotype AML, but also in cytogenetically abnormal AML (including AML with t(8;21), inv(16) and t(15;17)). AML cases with WT1 missense and in-frame insertion mutations express mutant WT1 mRNA at WT1 wild-type levels. These transcripts most probably encode proteins with impaired function because the mutations are located within the WT1 zinc fingers. The majority of WT1 aberrations were insertion/deletion mutations that introduced PTCs. Here, we show for the first time that mutant WT1 mRNA transcripts that carry PTCs are sensitive to NMD in primary AML. Consequently, these AML cases do not express the predicted truncated WT1 proteins. In these AML cases, mutations in WT1 may result in haploinsufficiency rather than expression of truncated WT1 proteins with impaired function. Haploinsufficiency and impaired function have been proposed as two possible mechanisms by which mutant WT1 may affect normal hematopoietic development. Surprisingly, in the WT1 mutant AML cases the wild-type WT1 protein is expressed at relatively high levels. Although, this phenomena has been shown in sporadic Wilms' tumors and some related syndromes, it is currently unclear whether the WT1 protein is pathogenic in these cases or whether it is related to the etiology of the cell of origin. 1 
